Financials data is unavailable for this security.
View more
Year on year Neuland Laboratories Ltd grew revenues 30.84% from 11.91bn to 15.59bn while net income improved 83.51% from 1.64bn to 3.00bn.
| Gross margin | 53.32% |
|---|---|
| Net profit margin | 20.55% |
| Operating margin | 27.35% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Neuland Laboratories Ltd increased its cash reserves by 92.83%, or 421.60m. The company earned 2.61bn from its operations for a Cash Flow Margin of 16.76%. In addition the company used 1.50bn on investing activities and also paid 692.82m in financing cash flows.
| Cash flow per share | 310.57 |
|---|---|
| Price/Cash flow per share | 40.93 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 40.00% and 83.51%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 0.44% |
|---|---|
| Div growth rate (5 year) | 63.45% |
| Payout ratio (TTM) | 5.34% |
| EPS growth(5 years) | 78.07 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 55.99 |
More ▼
